Filing Flows › Health Care › Theravance Biopharma (TBPH)
Theravance Biopharma (TBPH) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Theravance Biopharma (TBPH) Q2 2026 earnings results →
Q2 2026 Revenue down 21% year over year to $20.7M · 28¢ of every $1 of revenue lost · operating margin -39.9%
Theravance Biopharma made $20.7M in Q2 2026 (-21% Y/Y). Operating margin -39.9%, net loss $5.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $20.7M in Q2 2026, down 21% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $8.3M, an operating margin of -39.9%. Total costs grew 0% against a revenue fall of 21%. The quarter ended with a net loss of $5.9M, wider than the previous quarter's $4.9M loss. Non-operating items added $3.5M, -73% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$7.0M. Non-cash charges added back $6.0M of share-based compensation. Working capital and other items used $7.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $20.7M | -21% | -39.9% | −$5.9M | −$7.0M |
| Q1 2026 | 10-Q | May 7, 2026 | $17.7M | +15% | -53.6% | −$4.9M | $73.3M |
| Q4 2025 | 10-K | Mar 23, 2026 | $45.9M | +145% | 43.6% | $61.0M | −$6.1M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $20.0M | +18% | -32.3% | $3.6M | −$6.5M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $26.2M | +84% | -10.4% | $54.8M | $208M |
| Q1 2025 | 10-Q | May 12, 2025 | $15.4M | +6% | -93.8% | −$13.6M | $43.0M |
| Q4 2024 | 10-K | Mar 7, 2025 | $18.8M | +7% | -49.1% | −$15.5M | −$902K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Theravance Biopharma
Theravance Biopharma, Inc. (“we,” “our,” “Theravance Biopharma” or the “Company”) is a biopharmaceutical company primarily focused on the development and commercialization of medicines. Our focus is to deliver medicines that make a difference ® in people’s lives. In pursuit of our purpose, we leverage decades of expertise, which has led to the development of the United States (“US”) Food and Drug Administration (the “FDA”) approved YUPELRI ® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (“COPD”).
In its own words, from its 10-K, filed Mar 23, 2026.
Theravance Biopharma against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -21% against the peers' median +7%. Operating margin: -39.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TBPH Theravance Biopharma | Q2 2026 | $20.7M | -21% | -39.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Theravance Biopharma 10-Q on SEC EDGAR · CIK 1583107 · Pharmaceutical Preparations
More on TBPH
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results